PTO/SB/08A (04-07)

Approved for use through 09/30/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

bstitute for form 1449/PTO

Sheet

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

of

Coi	mplete if Known
Application Number	10/725,965
Filing Date	December 2, 2003
First Named Inventor	Erik Buntinx
Art Unit	1617
Examiner Name	Umamaheswari Ramachandran
Attorney Docket Number	29248/18

			U. S. PATEN	T DOCUMENTS	
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ^{2 (* known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
/U.R./	1	^{US-} 2002/0086899	07-04-2002	Sanchez et al.	
/U.R./	2	^{US-} 5,635,213	06-03-1997	Nystrom et al.	
		US-			
		US-			
		US-		*	
		US-			•
		US-			
		US-	1.	· · · · · · · · · · · · · · · · · · ·	
		US-			

		FORE	IGN PATENT DOCU	MENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
		Country Code ³ Number ⁴ "Kind Code ³ (if known)	MM-DD-YYYY		Or Relevant Figures Appear	Ţ
						┝
						L
						F
						₽

Examiner Signature	/Umamaheswari Ramachandran/	Date Considered	01/15/2008

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitut	e for form 1449/PTO				Complete if Known
0.000				Application Number	10/725,965
INFO	DRMATION	DIS	CLOSURE	Filing Date	December 2, 2003
STA	STATEMENT BY APPLICANT		First Named Inventor	Erik Buntinx	
	(Use as many she	ote se ni	praceant)	Art Unit	1617
	1030 as many sno	013 13 77	ccossary	Examiner Name	Umamaheswari Ramachandran
Sheet	2	of	2	Attorney Docket Number	29248/18

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
/U.R./	3	MÜLLER T, entitled "Drug treatment of non-motor symptoms in Parkinson's disease," Expert Opinion on Pharmacotherapy, 2002, Vol. 3, No. 4, pp. 381-388.	
	4	PERMAX prescription information, Eli Lilly Company, (http://www.fda.gov/medwatch/safety/2003/permax_Pl.pdf), revised October 2, 2003, pp. 1-2.	
	5	USPTO Office Action dated 05/03/2007 in connection with related Application Serial No. 10/803,793 filed 03/18/2004, Examiner Carlic K. Huynh, Art Unit 1617.	
	6	USPTO Office Action dated 0810/2007 in connection with related Application Serial No. 10/984,683 filed 11/09/2004, Examiner Carlic K. Huynh, Art Unit 1617.	
	7	USPTO Office Action dated 10/02/2007 in connection with related Application Serial No. 10/752,423 filed01/06/2004, Examiner Umamaheswari Ramachandran, Art Unit 1617.	
\bigvee	8	USPTO Office Action dated 10/19/2007 in connection with related Application Serial No. 10/803,793 filed 03/18/2004, Examiner Carlic K. Huynh, Art Unit 1617.	

Examiner Signature /Umamaheswari Ramachandran/ Date Considered 01/15/2008	
---	--

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08A (04-07)

AUG. 2 6 2007

Sheet

Approved for use through 09/30/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Col	mplete if Known
Application Number	10/725,965
Filing Date	December 2, 2003
First Named Inventor	Erik Buntinx
Art Unit	1617
Examiner Name	Umamaheswari Ramachandran
Attorney Docket Number	20240/40

Examiner Initials*	Cite No.1	Document Number Number-Kind Code ^{2 (# known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
/U.R./	1	US- 5,446,070	08-29-1995	Mantelle	
/U.R./	2	^{US-} 6,300,354	10-09-2001	Steiner et al.	
/U.R./	3	US- 2004/0002482	01-01-2004	Dudley et al.	
		US-			
		US- ·			
,		US-			
		US-			· · · · · · · · · · · · · · · · · · ·
		US-		 	
		US-			
		US-	•		
<u> </u>		US-			
		US-			

		FORE	IGN PATENT DOCU	MENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
		Country Code ³ "Number ⁴ "Kind Code ³ (if known)	MM-DD-YYYY		Or Relevant Figures Appear	T
						Ļ
1-1						╄
						L
		-				╄
						╄

Examiner Signature /Umamaheswari Ramachandran/ Date Considered 01/15/2008

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Skind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitut	te for form 1449/PTO				Complete if Known
Outsului	10 10 10 111 1443/7 10		•	Application Number	10/725,965
INFO	ORMATION	DIS	CLOSURE	Filing Date	December 2, 2003
STA	STATEMENT BY APPLICANT		First Named Inventor	Erik Buntinx	
	(Use as many she	ote ne n	neessand	Art Unit	1617
	(Use as many sne		ocessary)	Examiner Name	Umamaheswari Ramachandran
Sheet	2	of	2	Attorney Docket Number	29248/18

Examiner	Cite	NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of	
Initials*	No.1	the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/U.R./	4	HUBBLE J P et al., entitled "Pre-clinical studies of pramipexole: clinical relevance," European Journal of Neurology Supplement, 2000, Vol. 7 (Suppl. 1), pp. 15-20.	
/U.R./	5	SILVER D E et al., entitled "Initiating therapy for Parkinson's disease," Neurology, 1998, Vol. 50 (Suppl. 6), pp. S18-S22.	
+		·	

Examiner Signature /Umamaheswari Ramachandran/	Date Considered	01/15/2008
--	--------------------	------------

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 03/31/2007. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO	Complete if Known		
7 0000110101011011111111111111111111111	Application Number	10/725,965	
INFORMATION DISCLOSURE	Filing Date	December 2, 2003	
STATEMENT BY APPLICANT	First Named Inventor	Erik Buntinx	
(Use as many shoets as necessary)	Art Unit	1617	
(USe as many shoets as necessary)	Examiner Name	Umamaheswari Ramachandran	
Sheet of 1	Attorney Docket Number	29248/18	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
/U.R./	12	www.biam2.org/www/Sub2783.html, entitled "Pipamperone Dichlorhydrate," November 12, 2000, 1-4.	
	13	www.adiph.org/pic/pedia-neuroleptiques.pdf, entitled "Medicaments Psychotropes: Posologies Chez L'Enfant et L'Adolescent," August 2001, 1-3.	
	14	HEISER P et al., entitled "The selective serotonin reuptake inhibitors and the newer antidepressants in child and adolescent psychiatry," Zeitschrift fur Kinder - und Jugendpsychiatrie und Psychotherpie Switzerland 30: 2002, 173-183.	
15 Dopamine- reuptake inhibitor		CARLIER PR et al., "Synthesis of a Potent Wide-Spectrum Serotonin-, Norepinephrine-, Dopamine- reuptake inhibitor (SNDRI) and a species-selective dopamine reuptake inhibitor based on the gamma-amino alcohol functional group, Bioorgan. Medicin. Chem. Let. 8, 1998, 487-492.	
	16	FITZGERALD K D et al., entitled "Risperidone Augmentation of Serotonin Reuptake Inhibitor Treatment of Pediatric Obsessive Compulsive Disorder," Journal of Child and Adolescent Psychopharmacology, Vol. 9, No. 2, 1999, 115-123.	
	17	MCDOUGLE C J et al., entitled "A Double-blind. Placebo-Dontrolled Study of Risperidone Addition in Serotonin Reuptake Inhibitor-Refractory Obsessive-complusive Disorder," Arch Gen Psychiatry, Vol. 57, August 2000, 794-801.	
ŀ	18	MAINA G et al., entitled "Antipsychotic agumentation for treatment resistant obsessive-compulsive disorder: what if antipsychotic is discontinued," Int. Clin. Psychopharm, 18, 2003, 23-28.	
	19	HIROSE S et al., entitled "An Open Pilot Study Combining Risperidone and a Selective Serotonin Reuptake Inhibitor as Initial Antidepresant Therapy," J. Clin. Psych. 63, 2002, 733-736.	
Truffinet P et al., Placebo-controlled study of the D4/5-HT2A antagonist fananserin in the treatment of schizophrenia. Am J. Psychiatry 156: 419-425, 1999.			

Examiner	/Umamaheswari Ramachandran/	Date	
Signature	·	Considered	01/15/2008

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

PTO/SB/08B (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute to	r form 1449/PT0	`			Complete if Known		
300311101010	Goodman of the 1443/F 10				Application Number	10/725,965	
INFOR	NFORMATION DISCLOSURE				Filing Date	December 2, 2003	
STAT	EMENT	BY A	PPLI	CANT	First Named Inventor	Erik Buntinx	
	<i>(</i>)			•	Art Unit	1617	
	(Use as many s	ineets as n	өсөззагу)		Examiner Name	Umamaheswari Ramachandran	
Sheet	k	of		1	Attorney Docket Number	29248/18	

	(
	_	NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Т
/U.R./	12	www.biam2.org/www/Sub2783.html, entitled "Pipamperone Dichlorhydrate," November 12, 2000, 1-4.	
	13	www.adiph.org/pic/pedia-neuroleptiques.pdf, entitled "Medicaments Psychotropes: Posologies Chez L'Enfant et L'Adolescent," August 2001, 1-3.	
	14	HEISER P et al., entitled "The selective serotonin reuptake inhibitors and the newer antidepressants in child and adolescent psychiatry," Zeitschrift fur Kinder - und Jugendpsychiatrie und Psychotherpie Switzerland 30: 2002, 173-183.	
·	15	CARLIER PR et al., "Synthesis of a Potent Wide-Spectrum Serotonin-, Norepinephrine-, Dopamine- reuptake inhibitor (SNDRI) and a species-selective dopamine reuptake inhibitor based on the gamma-amino alcohol functional group, Bioorgan. Medicin. Chem. Let. 8, 1998, 487-492.	
	16	FITZGERALD K D et al., entitled "Risperidone Augmentation of Serotonin Reuptake Inhibitor Treatment of Pediatric Obsessive Compulsive Disorder," Journal of Child and Adolescent Psychopharmacology, Vol. 9, No. 2, 1999, 115-123.	
	17	MCDOUGLE C J et al., entitled "A Double-blind. Placebo-Dontrolled Study of Rispendone Addition in Serotonin Reuptake Inhibitor-Refractory Obsessive-complusive Disorder," Arch Gen Psychiatry, Vol. 57, August 2000, 794-801.	
	18	MAINA G et al., entitled "Antipsychotic agumentation for treatment resistant obsessive-compulsive disorder: what if antipsychotic is discontinued," Int. Clin. Psychopharm, 18, 2003, 23-28.	
	19	HIROSE S et al., entitled "An Open Pilot Study Combining Risperidone and a Selective Serotonin Reuptake Inhibitor as Initial Antidepresant Therapy," J. Clin. Psych. 63, 2002, 733-736.	
V	20	Truffinet P et al., Placebo-controlled study of the D4/5-HT2A antagonist fananserin in the treatment of schizophrenia. Am J. Psychiatry 156: 419-425, 1999.	

ı	Examiner	/Umamaheswari Ramachandran/	Date	04/45/0000	l
ı	Signature		Considered	01/15/2008	ĺ

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

Sheet

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known Application Number 10/725,965 Filing Date December 2, 2003 Erik Buntinx First Named Inventor Art Unit 1617 **Examiner Name** Jennifer M. Kim Attorney Docket Number 29248/18

Examiner Initials*	Cite No.1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where	
		Number-Kind Code ^{2 (# known)}	MIM-DD-1111	Applicant of Cited Document	Relevant Passages or Relevant Figures Appear	
/U.R./	1	^{US-} 5,780,474 A	07-14-1998	Brocco et al.		
/U.R./	2	^{US-} 5,762,960 A	06-09-1998	Dodman		
/U.R./	3	^{US-} 5,364,857 A	11-15-1994	Bode Greuel		
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-		,		
		US-				
		US-				
		US-				
		US-				
		US				
		US-				
		US-				
. ,		US-				

			FOREIG	GN PATENT DOCL	IMENTS		
1	Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
			Country Code ³ Number ⁴ Kind Code ⁵ (if known)	MM-DD-YYYY		Or Relevant Figures Appear	T [®]
	/U.R./	4	WO 01/98298 A	12-27-2001	H. LUNDBECK A/S		
ſ	Ī	5	WO 98/43646 A	10-08-1998	AKZO NOBEL N.V.		
		6	WO 98/11897 A	03-26-1998	ELI LILLY AND COMPANY		
		7	WO 00/64441 A	11-02-2000	RESPIRATORIUS AB		
	V	8	WO 02/051833 A	07-04-2002	E.C.L.		
ſ							

Examiner Signature	/Umamaheswari Ramachandran/	Date Considered	01/15/2008

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Senter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 If possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substit	ute for form 1449/PT	· O		Complete if Known		
Jubstit	U(8 101 101111 1449/F 1			Application Number	10/725,965	
INIE	CODMATI	או דוכ	CLOSURE	Filing Date	December 2, 2003	
				First Named Inventor	Erik Buntinx	
ST	ATEMEN1	BY A	PPLICANT	Art Unit	1617	
	(Use as many	sheets as n	ecessary)	Examiner Name	Jennifer M. Kim	
Sheet	2	of	6	Attorney Docket Number	29248/18	

			U. S. PATEN	DOCUMENTS	
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ^{2 (# known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
/U.R./	44	^{US-} 2005/0119248	06-02-2005	Buntinx .	
/U.R./	45	^{US-} 2005/0119249	06-02-2005	Buntinx	
		US-			
		US-		7	
		US-			
		US-	-		
		US-			
		US-			
		US-			
		US-			

		FORE	IGN PATENT DOCL	IMENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
		Country Code ³ -Number ⁴ -Kind Code ³ (if known)	MM-DD-YYYY		Or Relevant Figures Appear	Т
/U.R./	9	DE 40 39 631 A	06-17-1992	Troponwerke GmbH &		
_				Co KG		
						L
						L
						L
•						

Examiner Signature	/Umamaheswari Ramachandran/	Date Considered	01/15/2008

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.usplo.gov or MPEP 901.04. Senter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 If possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

a collection of information unless it seems.

Substitut	te for form 1449/PTO			Complete if Known		
Substitut	10 10 10 11 144 5 1 1 0			Application Number	10/725,965	
INFO	ORMATION	I DIS	CLOSURE	Filing Date	December 2, 2003	
STA	TEMENT B	BY A	PPLICANT	First Named Inventor	Erik Buntinx	
	(Use as many sh	sote as su	occessed.	Art Unit	1617	
	(Cae as many an	0013 43 11	ucessary)	Examiner Name	Jennifer M. Kim	
Sheet	3	of	6	Attorney Docket Number	29248/18	

			NON PATENT LITERATURE DOCUMENTS	_
		No. the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
/U.R./		10	SCHINDLER T et al., entitled "Palliative medical management in anxiety and depression," Zeitschrift Fur Allgemeinmedizin, Vol. 74, No. 21, November 5, 1998, pp. 973-978.	
		11	VOLMAT R et al., entitled "The treatment of depressions by Cledial. Evolution and clinical state and handwriting," Psychologie Medicale, Vol. 18, No. 10, 1986, pp. 1615-1622.	
		12	FOUKS et al., entitled "Treatment of character disorders with a new butyrophenone: R. 3345 or pipamperone," Annales Medico-Psychologiques, Vol. 124, No. 5, 1966, pp. 677-681.	
-		13	SQUELART P et al., entitled "Pipamperone (Dipiperon), a useful sedative neuroleptic drug in troublesome chronic psychotic patients," Acta Psychiatrica Belgica, Vol. 77, No. 2, March 1977, pp. 284-293.	
		14	KOCH H J et al., entitled "Successful therapy of tardive dyskinesia in a 71-year-old woman with a combination of tetrabenazine, olanzapinr and tiapride," International Journal of Clinical Practice, Vol. 57, No. 2, March 2003, pp. 147-149.	
		15	DIEBOLD K et al., entitled "Are psychoactive-drug-induced changes in plasma lipid and lipoprotein levels of significance for clinical remission in psychiatric disorders?" Pharmacopsychiatry, 1998, 31/2, pp. 60-67.	
		16	GROZINGER M et al., entitled "Melperone is an inhibitor of the CYP2D6 catalyzed 0-demethylation of venlafaxine," Pharmacopsychiatry, Vol. 36, No. 1, January 3003, pp. 3-6.	
	÷	17	PERUGI G et al., entitled "Effectiveness of Adjunctive Gabapentin in Resistant Bipolar Disorder: Is it due to anxious-alcohol abuse comorbidity?" Journal of clinical Psychopharmacology, Vol. 22, No. 6, 2002, pp. 584-591.	
		18	WIELING W et al., entitled "Initial orthostatic hypotension as a cause of recurrent syncope: A case report," Clinical Autonomic Research, Vol. 11, No. 4, 2001, pp. 269-270.	
Ψ	′	19	DATABASE PHARMAPROJECTS 'ONLINE! PJB Publications Ltd., December 1999. Caesar accession no. 1498	

,			<i>-</i>
Examiner	/I Imamahaayyari Damaahandran/	Date	
Signature	/Umamaheswari Ramachandran/	Considered	l 01/15/2008
Signature		Considered	,

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute	e for form 1449/PTO			Complete if Known		
Substitute	9 101 101111 1440/1 10			Application Number	10/725,965	
INFO	RMATION	N DIS	CLOSURE	Filing Date	December 2, 2003	
STA	TEMENT	BY A	PPLICANT	First Named Inventor	Erik Buntinx	
	(the seminary of	4		Art Unit	1617	
	(Use as many sh	ieets as n	ecessary)	Examiner Name	Jennifer M. Kim	
Sheet	4	of	6	Attorney Docket Number	29248/18	

		NON PATENT LITERATURE DOCUMENTS	
Examine Initials*	er Cite No. Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
/U.R.	20	ADLER L et al., entitled "Praxis Der Stationaeren Akutbehandlung Von Manien Retrospektive Vergleichsuntersuchung An Je 100 Patienten Zweier Psychiatrischer Sentren Practice of In-Patient Acute Treatment of Manias," Fortschritte Der Neurologie	
		Psychiatrie, Stuttgart, Vol. 62, No. 12, 1994, pp. 479-488.	
	21	ANSOMS C et al., entitled "Sleep disorders in patients with severe mental depression: double-blind placebo-controlled evaluation of the value of pipamerone (Dipiperon)," Acta Psychiatrica Scandinavica," Vol. 55, No. 2, February 1977, pp. 116-122.	
	22	LEYSEN J E et al., entitled "Receptor interactions of new antipsychotics: Relation to Pharmacodynamic and Clinical Effects," International Journal of Psychiatry in Clinical Practice, Vol. 2, No. 1, 1998, pp. S03-S17.	
	23	VANHOENACKER P et al., entitled "Efficient Expression of the Human Dopamine D4.2 Receptor: Positive Influence of Pipamperone on Expression Levels," Abstracts of the Society for Neuroscience, Vol. 26, No. 1/2, 2000.	
	24	SCHOTTE A et al., entitled "Risperidone compared with new and reference antipsychotic drugs: In vitro and in vivo receptor binding," Psychopharmacology, Vol. 124, No. 1-2, 1996, pp. 57-73.	
	25	WOGGON B, entitled "Pharmakologische depressionbehandlung pharmacological treatment of depression," Therapeutische Umschau, Vol. 57, No. 2, 2000, pp. 81-89.	
	26	VAN DE VIJVER DAMC et al., entitled "Antipsychotics and Parkinson's disease: Association with disease and drug choice during the first 5 years of antiparkinsonian durg treatment," Eur J Clin Pharmacology, Vol 58, 2002, pp. 157-161.	
V	27	JOVIC NI et al., entitled "Phenomenology and treatment of delirium in Alzheimer's disease!" Revue Medicale De La Suisse Romande, Vol. 117, No. 9, September 1997, pp. 655-658.	

Examiner	/Umamaheswari Ramachandran/	Date	01/15/2009
Signature	/ omananoovan namasharara	Considered	01/15/2008

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

PTO/SB/08B (08-03)
Approved for use through 07/31/2006, OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
a collection of information unless it contains a valid OMB control

Substitut	e for form 1449/PTO			Complete if Known		
Cabbinat	o loi yomi yayon yo			Application Number	10/725,965	
INFO	ORMATION	DIS	CLOSURE	Filing Date	December 2, 2003	
STA	TEMENT E	BY A	PPLICANT	First Named Inventor	Erik Buntinx	
	(Use as many she	ate se n		Art Unit	1617	
	(030 as many and	013 03 77		Examiner Name	Jennifer M. Kim	
Sheet	5	of	6	Attorney Docket Number	29248/18	

		NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	No. ¹ the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.					
/U.R./	28	ENGELBORGHS S et al., entitled "Amino acids and biogenic amines in cerebrospinal fluid of patients with Parkinson's disease," Neurochemical Research, Vol. 28, No. 8, August 2003, pp. 1145-1150.				
	29	NEWMAN-TANCREDIT A et al., [35S]-guanosine-5'-0-(3-thio) triphosphate binding as a measure of efficacy at human recombinant dopamine D-4.4 receptors: Actions of antiparkinsonian and antipsychotic agents. Journal of Pharmacology and				
		Experimental Therapeutics, Vol. 282, No. 1, 1997 pp. 181-191.				
	30	TARAZI F I et al., entitled "Role of dopamine D4 receptors in neuropsychiatric disorders," Journal of Neurochemistry, Vol. 81, No. Supplement 1, June 2002, p. 33. Abstract				
	31	TARAZI F I et al., entitled "Dopamine D4 Receptors: Significance for Molecular Psychiatry at the Millennium," Molecular Psychiatry, Vol. 4, No. 6, November 1999, pp. 529-538.				
	32	LEOPOLD N A, entitled "Risperidone treatment of drug-related psychosis in patients with parkinsonism," Movement Disorders. Vol. 15, No. 2, March 2000, pp. 301-304.				
		·				
	33	HADJ TAHAR A et al., entitled "Antidyskinetic effect of JL-18, a clozapine analog, in parkinsonian monkeys," European Journal of Pharmacology, Vol. 399, No. 2-3, July 7, 2000, pp. 183-186.	·			
	34	ZESIEWICZ TA et al., entitled "Clozapine withdrawal symptoms in a Parkinson's disease patient," Movement Disorders: Vol. 17, No. 6, November 2002, pp. 1365-1367.				
\bigvee	35	FALTRACO F et al., Akuelle Therapiemoglichkeiten der Alzheimer Demenz (Current Therapeutical Strategies in Dementia), Neurol Rehabil 2003; 9 (1), pp.15-22.				

Examiner /Umamaheswari Ramachandran/	Date Considered	01/15/2008
--------------------------------------	--------------------	------------

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant,

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the Individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

	te for form 1449/PTO			re required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known		
				Application Number	10/725,965	
INF	ORMATION	DIS	CLOSURE	Filing Date	December 2, 2003	
STA	TEMENT E	BY A	PPLICANT	First Named Inventor	Erik Buntinx	
	(Use as many she	ante se n	arecsani)	Art Unit	1617	
	loso as many sine	1013 d3 II		Examiner Name	Jennifer M. Kim	
Sheet	6	of	6	Attorney Docket Number	29248/18	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	
/U.R./	36	ETCHEPAREBORDA M C, entitled "Neurocognitive and pharmacological approach to specific learning disorders," Database Medline "Online!, US National Library of Medicine, February 1999, and Revista De Neurologia, Vol. 28, Suppl. 2, February 1999, pp. S81-S93, Abstract.	
	37	STAHL S M et al., entitled "Examination of nightime sleep-related problems during double-blind, placebo-controlled trials of galantamine in patients with Alzheimer's disease," Current Medical Research and Opinion 2004, Vol. 20, No. 4, 2004, pp. 517-524.	
	38	MENESES A et al., entitled "Are 5-HT (1B/1D) and 5-HT (2A/2B/2C) receptors involved in learning and memory processes?" IDrugs 1999, Vol. 2, No. 8, 1999, pp. 796-801.	
	39	WIRZ-JUSTICE A et al., entitled "Haloperidol disrupts, clozapine reinstates the circadian rest-activity cycle in a patient with early-onset Alzheimer disease," Alzheimer Disease and Associated Disorders, Vol. 14, No. 4, 2000, pp. 212-215.	
	40	FAHS H et al., entitled "Thymoregulateurs Dans L'Agitation et les Troubles Du Comportement Chez le Sujet Dement a Propos de Huit Cas, Anticonvulsivants and Aggresive Behaviors in Alzheimer's Disease. Eight Cases Reports," L'Encephale	
		Vol. 25, No. 2, 1999, pp. 169-174.	
	41	WERTH E et al., entitled "Decline in long-term circadian rest-activity cycle organization in a patient with dementia," Journal of Geriatric Psychiatry and Neurology, Vol. 15, No. 1, April 2002, pp. 55-59.	
	42	MELTZER HY et al., entitled "Plasma clozapine levels and the treatment of L-Dopa-induced psychosis in Parkinson's disease. A high potency effect of clozapine," Neuropsychopharmacology, Vol. 12, No. 1, 1995, pp. 39-45.	
\bigvee	43	MUNCHAU A et al., entitled "Pharmacological Treatment of Parkinson's Disease," Postgraduate Medical Journal, Vol. 76, October 2000, pp. 602-610.	
•			
			<u></u>

Examiner Signature /Umamaheswari Ramachandran/	Date Considered	01/15/2008
--	--------------------	------------

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant,

Considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.